Detected ·
Circle Pharma, Inc.
——
Circle Pharma, Inc. announced an oversubscribed Series E financing led by The Column Group, to advance CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, through early clinical development for ER-positive breast cancer.
- Website
- www.circlepharma.com
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-09-17 08:03:05 UTC
- Signal ID
- 9f6660f7-949f-4196-b11c-19378ea4ae27
As the API returns it
{
"id": "9f6660f7-949f-4196-b11c-19378ea4ae27",
"created_at": "2026-09-17T08:03:05.619652Z",
"company_name": "Circle Pharma, Inc.",
"company_website_url": "www.circlepharma.com",
"company_linkedin_url": "https://www.linkedin.com/company/circle-pharma-inc-",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Circle Pharma, Inc. announced an oversubscribed Series E financing led by The Column Group, to advance CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, through early clinical development for ER-positive breast cancer.*"
}